Non-invasive test for diagnosis bladder cancer

August 18, 2015 News BioVox

Bladder cancer is the fifth most common cancer in the western world.  MDxHealth developed a urine-based bladder cancer test for patients with hematuria (blood in urine). The test will provide physicians with a cost-effective, patient-friendly diagnostic tool to accurately detect bladder cancer and monitor recurrence.

A cohort study of 154 patients with hematuria showed that the test has a negative predictive value of 98.3%. The test is based on a combination of DNA methylation biomarkers, that were developed by MDxHealth and University Erasmus Medical Center. The latter party will receive milestone payments and royalties from MDxHealth.


Avatar photo
BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter